Following injury, leukocytes are released from hematopoietic organs and migrate to the site of damage to regulate tissue inflammation and repair, however leukocytes lacking β2-adrenergic receptor (β2AR) expression have marked impairments in these processes. β-blockade is a common strategy for the treatment of many cardiovascular etiologies, therefore the objective of our study was to assess the impact of prior β-blocker treatment on baseline leukocyte parameters and their responsiveness to acute injury. In a temporal and βAR isoform-dependent manner, chronic β-blocker infusion increased splenic vascular cell adhesion molecule-1 (VCAM-1) expression and leukocyte accumulation (monocytes/macrophages, mast cells and neutrophils) and decreased chemokine receptor 2 (CCR2) expression, migration of bone marrow (BM) and peripheral blood leukocytes (PBL), as well as infiltration into the heart following acute cardiac injury. Further, CCR2 expression and migratory responsiveness was significantly reduced in the PBL of patients receiving β-blocker therapy compared to β-blocker-naïve patients. These results highlight the ability of chronic β-blocker treatment to alter baseline leukocyte characteristics that decrease their responsiveness to acute injury and suggest that prior β-blockade may act to reduce the severity of innate immune responses.
Introduction
Leukocytes are rapidly recruited to sites of acute injury where they regulate a wide variety of remodeling responses including inflammation, fibrosis and scar stabilization to promote wound healing (1) (2) (3) (4) . This early immune response includes the recruitment of inflammatory leukocytes, including granulocytes such as neutrophils and mast cells, as well as phagocytic monocytes, to attract further leukocyte recruitment and begin clearing the area of dead cells and debris (5, 6) .
Intense early and/or prolonged recruitment of inflammatory leukocytes can lead to maladaptive tissue remodeling/scar formation over time, with a negative impact on organ function, such as increased stiffness that reduces cardiac output following myocardial infarction (MI) (7, 8) .
Dampening leukocyte infiltration following injury has been shown capable of reducing subsequent maladaptive remodeling outcomes (8) (9) (10) (11) (12) , therefore identifying therapeutics that reduce leukocyte responsiveness to acute injury is of great interest.
Acute injury events activate the sympathetic nervous system to regulate a host of immune system functions in part via activation of β-adrenergic receptors (βAR) (13) , therefore understanding whether βAR-mediated regulation of immune cells impacts their response to injury may offer insight into how this process may be modulated. To this end, we previously developed chimeric mice lacking β2AR expression in cells of hematopoietic origin via transplantation of β2AR knockout (KO) bone marrow (BM) into wild-type (WT, C57Bl6/J) recipient mice and subjected them to MI. Strikingly, these chimeric mice displayed severe changes in several leukocyte parameters, including increased splenic vascular cell adhesion molecule-1 (VCAM-1) expression and leukocyte retention, as well as decreased bone marrow cell (BMC) expression of chemokine receptor 2 (CCR2) and post-injury leukocyte recruitment to the heart (14, 15) . Collectively, these genetic studies suggested that since complete β2AR deletion negatively regulates leukocyte behavior both at baseline and following injury, clinically used β-blockers may also impact leukocyte responsiveness to acute injury. β-blockers have been used successfully for decades to treat several pathologies, including hypertension, congestive heart failure and post-MI dysfunction (16) . Many of the benefits of β-blockers are thought to be mediated via their direct actions on cardiac-expressed βAR to decrease cardiac output when administered after an event such as MI, or to decrease infarct size at the time of reperfusion as recently reported (17) . However, the impact of prior β-blocker usage on immune cell function and responsiveness in human subjects is not well-documented. We previously observed that β-blocker treatment of human macrophages increased VCAM-1 expression, similar to macrophages derived from β2ARKO mice, and VCAM-1 expression was increased in the spleens of human subjects treated chronically with β-blocker (14) . These results revealed that prior β-blocker treatment can alter the molecular signature of leukocytes, potentially impacting their function and responsiveness to acute injury. Thus, in our current study, we used mouse models and leukocytes from patients to examine whether chronic β-blocker treatment alters leukocyte splenic localization, chemokine receptor expression and migration to decrease their responsiveness to acute injury in vivo. Our results demonstrate that chronic treatment with β-blockers decreases leukocyte responsiveness in both murine models and human peripheral blood leukocytes (PBL), suggesting that β-blockers with β2AR selectivity are capable of finetuning innate immune responses to injury in vivo.
Results

β-blocker infusion alters splenic leukocyte parameters over time in vivo.
Our previous studies identified key molecular changes in leukocytes in response to hematopoietic cell-specific deletion of β2AR, including increased splenic VCAM-1 expression and leukocyte retention, as well as decreased leukocyte CCR2 expression in BM-derived leukocytes (14, 15) . Therefore, we aimed to determine whether prior treatment with β2AR-selective and/or clinically-used β-blockers would similarly alter these leukocyte parameters. To this end, WT C57BL/6 mice were administered via osmotic minipump either vehicle, ICI-118,551
(ICI, a β2AR-selective antagonist), carvedilol (Carv, a non-selective adrenergic receptor antagonist), a low dose of the β1AR-selective antagonist metoprolol (Met Low), which has been shown to be selective for β1AR (18) (19) (20) and to block cardiac β1AR-mediated contractility (Supplemental Figure 1A) , or a high non-selective dose of metoprolol (Met High) (21, 22) . Similar to changes in splenic parameters we reported in β2ARKO BMT mice, infusion of mice with ICI resulted in a temporally-dependent increase in spleen size and splenic VCAM-1 expression ( Figure 1A-D) , which peaked after 2 weeks of infusion. Using this timepoint, the impact of metoprolol and carvedilol were also tested, revealing that both Met High and Carv increased spleen size and splenic VCAM-1 expression, while Met Low did not impact these parameters ( Figure 1E-H) .
Previously, enhanced spleen size and VCAM-1 expression secondary to loss of leukocyteexpressed β2AR was shown to correlate with increased splenic retention of various leukocyte populations, including monocytes/macrophages, neutrophils and mast cells (14) . Thus, initially using immunohistochemical analysis we quantified the amount of these leukocyte populations within the splenic red pulp and white pulp (Supplemental Figure 1B CCR2 mediates the recruitment of leukocytes to sites of injury in response to its ligand CCL2 (8, 10, 23, 24) . Since we had previously reported that complete loss of β2AR expression in leukocytes resulted in a marked reduction in CCR2 expression and BMC responsiveness to CCL2-mediated migration(15), we tested whether β-blocker infusion is also sufficient to alter these parameters. Indeed, infusion with ICI reduced BMC-expressed CCR2 in a temporally-dependent manner ( Figure 4A ), while infusion with Carv or Met High for 2 weeks also resulted in decreased BMC CCR2 expression and Met Low had no impact ( Figure 4B ). Via flow cytometry, decreased levels of CD45 + /CCR2 + (hematopoiesis-derived CCR2 + cells) in BMC following 2 weeks of ICI infusion was also confirmed ( Figure 4C-D) . Molecular changes within the BM do not necessarily represent those that may occur in circulating leukocytes, thus we sought to determine whether the same responses to β-blockers we observed in isolated BMC could also be detected in PBL.
To this end, we isolated buffy coats containing the PBL population from mice treated with each β-blocker for 2 weeks and measured CCR2 expression. Similar to our observations in BMC, CCR2
expression was significantly decreased in PBL chronically exposed to ICI, Carv and Met High, but not Met low ( Figure 4E ). Since CCR2 expression was reduced in both BMC and PBL by β2AR-selective β-blockade, we tested whether these cells exhibited impaired migration toward CCL2.
Responsiveness to CCL2 was almost completely abrogated in both BMC and PBL by prior infusion with ICI, Carv or Met High ( Figure 5A-C) . In contrast, CCL2-mediated migration was unaffected in either leukocyte population attained from Met Low-infused mice.
Although mice provide a useful in vivo model to explore the effects of β-blocker treatment on leukocytes, we aimed to determine whether our results translate to human leukocyte biology.
Therefore, to determine whether a molecular readout of β-blocker-mediated changes in leukocytes can be also detected in human PBL, we analyzed CCR2 expression and responsiveness in buffy coat samples attained from patients treated chronically with or without β-blockers. Similar to our data attained in mice, CCR2 expression was significantly reduced in the PBL of patients who had been receiving chronic β-blocker therapy compared to β-blocker-naïve patients (Table 1 ). Further, PBL of patients having received chronic β-blocker treatment displayed reduced migratory responsiveness to CCL2 ( Figure 5D -E). In all, these data highlight the translatability of our mouse model data toward clinical relevance in humans.
Prior β-blocker infusion reduces leukocyte responsiveness to injury in vivo.
We previously reported that mice with β2AR deletion specifically in cells of hematopoietic origin displayed reduced infiltration of leukocytes into the heart following acute myocardial infarction (MI) (14, 15) . Since chronic infusion with β-blockers induced similar baseline changes in both splenic and BM leukocytes as observed in β2ARKO BMT mice, populations which are integral to post-injury innate immune responses (2, 5, 6, 25) , we sought to determine whether chronic β-blocker treatment impacts leukocyte responsiveness to MI-induced injury. Therefore, While all mice receiving MI experienced a significant reduction in contractility compared to shamoperated mice as estimated by ejection fraction (Supplemental Figure 3A) , there were no significant post-MI differences between any of the β-blocker pretreatment groups. However, prior treatment with either ICI, Carv or Met high did significantly reduce survival by ~50-60% within the first week due to increased cardiac rupture events ( Figure 6D ) such that there were limited mice remaining in some groups with which to assess cardiac function. Met low did not significantly reduce survival when compared to Veh-infused mice.
Since β2ARKO BMT mice experienced 100% mortality following MI (14), but β-blockerinfused mice displayed variable mortality outcomes, these data suggest an intermediate effect of 
Discussion
We previously demonstrated that wild-type mice having received transplantation of β2ARKO BM, in which β2AR signaling was completely absent in leukocytes, were unable to achieve leukocyte egress from the spleen and recruitment to the heart following MI (14, 15) . These data suggested that β-blockers, used extensively in the treatment of numerous clinical etiologies, could act to alter the molecular characteristics of leukocytes at baseline and reduce their responsiveness to acute injury. Therefore, in this study, we examined the impact of prior treatment with both β2AR-selective and clinically-used β-blockers on several leukocyte parameters, including splenic localization, CCR2-mediated migration and recruitment to the heart following injury. Indeed, we demonstrate that chronic treatment with β2AR-selective and nonselective β-blockers altered baseline splenic expression of VCAM-1 and leukocyte localization, as well as leukocyte-specific CCR2 expression and responsiveness to CCL2-mediated migration.
Further, mice that underwent prior treatment with β2AR-selective and non-selective β-blockers displayed significantly impaired recruitment of leukocytes to the injured heart. While in accordance with our previous studies (14, 15) , this study specifically highlights several important facets of the impact of prior β-blocker treatment on leukocyte responsiveness to injury.
First, β2AR selectivity is critical in the ability of a β-blocker to impart effects on splenic accumulation and leukocyte recruitment to the site of injury. Pretreatment of mice with ICI 118,551, a strong inverse β2AR agonist (26) , carvedilol, a non-selective βAR antagonist, and a high non-selective dose of the neutral β1AR antagonist metoprolol (21) , each increased splenic VCAM-1 expression and leukocyte accumulation while reducing leukocyte CCR2 expression and responsiveness to injury as well as post-MI survival. Most compellingly, metoprolol did not modulate leukocyte molecular parameters or responsiveness when infused at a low β1AR-selective dose, which still blocked catecholamine-induced cardiac contractility. These results suggest that both carvedilol and metoprolol, when used at a non-selective dose, allow β2AR
antagonism that can alter the molecular blueprint of leukocytes and their resulting ability to respond to acute injury. However, via allometric scaling from a human average weight of ~85kg in our study (Table 1) , the dose of carvedilol used in this study (10mg/kg/day in mice) produces a human equivalent dose of ~70mg/day, which is greater than the maximal dose used in the SELECT trial (50mg/day) (21, 22) . Similarly the Met High dose used in our study equates to ~350mg/day in an 85kg human, above the maximal dose of 200mg/day used in the SELECT trial, while the Met Low dose produces a human equivalent dose of ~7mg, well below the lowest dose of metroprolol (25mg/day) used in the SELECT trial (21, 22) . Thus, it would be expected that the doses of Carv and Met High used in our study may cause more severe changes in leukocyte parameters than would be observed in humans receiving β-blockers within clinically-used ranges.
Indeed, our transwell migration data is consistent with this notion, as prolonged infusion with either Carv or Met High completely ablated isolated mouse leukocyte migration (no fold change in response to CCL2), whereas PBL isolated from β-blocker treated humans retained some responsiveness to CCL2 (~2-fold change in migration). Therefore, while we provide a useful proof-of-concept study depicting the action of β2AR-selective β-blockers on in vivo leukocyte biology, further studies employing a range of doses of clinically-used β-blockers with varying β2AR-selectivities will be most informative in terms of defining thresholds of molecular changes produced by chronic β-blocker treatment. In fact, titration of β-blocker dosage could be achieved in which leukocyte responsiveness is partially, but not fully, diminished to promote a more restrained innate immune response that allows for tissue repair, but with reduced long-term inflammation.
Second, β-blocker treatment that precedes an injury may dampen leukocyte responsiveness to that injury, thereby reducing the inflammatory insult and potentially relaying better outcomes. Of note, while we observed that longer β-blocker infusion regimens (≥ 2 weeks)
were required to significantly alter the molecular signatures of leukocytes at baseline or in response acute cardiac injury, we did not test the impact of β-blocker treatment on leukocyte parameters for less than 1 week. To this point, work by the Ibáñez group has demonstrated a benefit of metoprolol infusion beginning just prior to reperfusion following MI in humans (METOCARD-CNIC trial patients) and pigs (17) , which in a follow-up study was mechanistically linked with the direct negative regulation of neutrophil function and was associated with decreased myocardial injury in mice (27) . Thus, the duration of β-blocker treatment necessary to dampen immune cell responses, but not negatively impact MI-induced scar formation and survival, is an open question, though this may be less of a concern than β-blocker dosage/selectivity.
Third, there is likely a critical washout period after cessation of β-blocker infusion in which full leukocyte responsiveness to acute injury may be restored. For instance, our initial experiments in which we established the impact of β-blocker infusion at baseline showed a marked increase in splenic hypertrophy and retention of leukocytes, while our subsequent studies in which we discontinued β-blocker infusion 1 day prior to sham or MI surgery and performed cellular and tissue analyses another 4 days later (5 days total following β-blocker cessation), splenic parameters were almost normalized even in the sham-operated mice. In contrast, our previous work showed that chimeric mice lacking β2AR expression in cells of hematopoietic origin exhibited baseline splenomegaly that increased in conjunction with leukocyte retention following cardiac injury, with correspondingly worsened leukocyte infiltration to the heart, which was partially relieved by splenectomy (14) . Although splenic parameters were normalized after β-blocker discontinuation, the β-blocker-mediated decrease in leukocyte CCR2 expression and CCL2-mediated migration following injury were retained even 5 days following cessation of infusion, indicating a prolonged impact of β-blockade on CCR2 signaling in leukocytes. This observation points out that other β-blocker-sensitive cell types, including those in the heart, may still be altered at a molecular level similar to leukocytes, thereby contributing to the post-MI outcome. However, there were no differences in post-MI infarct size or cardiac function in the vehicle versus β-blocker treatment groups, suggesting that the initial response to acute MI was similar across all cohorts and that reduced immune cell infiltration into the heart by 4 days post-MI was specifically due to altered leukocyte CCR2 expression and responsiveness. The intermediate phenotype of restored splenic leukocyte profile but reduced CCR2-mediated responsiveness could explain why β-blocker-treated mice experienced less post-MI mortality than we previously observed with leukocyte-specific genetic ablation of β2AR (14) . It also suggests that a longer washout period between β-blocker cessation and injury is required to fully recover innate immune system responsiveness to injury.
While there are conflicting reports of the effects of the sympathetic nervous system on regulating the CCL2/CCR2 axis, with some showing no effect (28) and others showing decreased CCR2 in response to either non-selective AR activation (29) or β-blockade(30), previous findings in our laboratory have shown that deletion of hematopoietic β2AR almost completely ablates CCR2 expression (15) . In accordance with our previous findings, this study demonstrates that chronic pharmacological inhibition in vivo, with increasing duration and selectivity toward β2AR, decreases CCR2 expression in both BMC and PBL. Further, our clinical data highlight the translational relevance of our studies in mice since CCR2 expression and CCL2 responsiveness were also decreased in the buffy coat samples of patients having taken a β-blocker chronically versus β-blocker naïve patients. Although interpretation of human data can be made difficult by variability between patient treatment and control groups, the alterations in CCR2 expression and responsiveness we observed in human peripheral blood leukocytes occurred irrespective of underlying conditions in the patient populations, since both β-blocker-treated and β-blocker naïve cohorts were comprised of patients with hypertension, diabetes mellitus, coronary artery disease and heart failure. Therefore, CCR2 expression levels in PBL may represent a molecular biomarker for predicting the potential impact/outcomes of chronic β-blocker treatment on leukocyte-dependent responsiveness to acute injury, which will require further assessment.
Beyond use as a biomarker in this regard, CCR2 has been explored more generally as a potential therapeutic target in injury and disease models (31) . Classical inflammatory monocytes express high levels of CCR2, while non-classical reparative monocytes lack CCR2 expression (23) . Previous studies have shown the importance of CCR2 in mediating classical monocyte recruitment to the heart following MI, and more recently pressure overload, and the impact of deleting CCR2 expression genetically or via siRNA on preventing this response to improve outcomes in mice (10, 24, 32) . Thus, inhibition of CCR2 remains a viable strategy to dampen the inflammatory response after injury, though gene deletion or siRNA strategies to alter CCR2 expression in vivo remains more challenging than a pharmacologic approach. As such, selective targeting of inflammatory monocytes via β-blocker-mediated decreases in CCR2 expression may provide a strategy by which to decrease pathologic remodeling following tissue injury while not interfering with reparative monocyte/macrophage processes.
In summary, our study demonstrates that clinically relevant β-blockers modulate several leukocyte parameters at a molecular level, including VCAM-1 and CCR2 expression, thereby altering their splenic localization and migration, respectively, and reducing their responsiveness to injury. The use of clinical samples in this study suggests that chronic β-blocker treatment also alters leukocyte parameters in humans. Whether this impacts leukocyte responsiveness to acute injury events in humans and the subsequent remodeling outcomes remains to be tested vigorously. Thus, an expanded investigation into the impact of selectivity, dosage and duration of β-blocker usage on human leukocyte function would offer clinical insight and drive further translational research using preclinical models.
Methods
Experimental animals. Wild-type (WT) C57Bl/6 male mice aged 10-12 weeks, attained from
The Jackson Laboratory, were used in this study to determine the impact of prior β-blocker infusion on parameters including splenic and cardiac accumulation of leukocytes before and after acute injury, alterations in expression of adhesion and chemokine receptors as well as leukocyte chemotaxis. WT mice were randomized into groups that were administered vehicle (Veh, sterile Coronary Artery Occlusion Surgery. Myocardial infarction was induced as previously described (14, 15) . In brief, mice were anesthetized with 2% isoflurane inhalation. A small skin incision was made and the pectoral muscles were dissected and retracted to expose the fourth intercostal space. A small hole was made and the heart popped out. The left coronary artery was sutured ~3 mm from its origin and the heart was placed back into the intrathoracic space and closure of muscle and skin. Animals received a single dose (0.3 mg/kg) of buprenorphine immediately following surgery. Injury level from myocardial infarction surgery was standardized by a predefined parameter as having an ejection fraction of <40% as measured by echocardiography 4 days post-MI, whereas animals having an ejection fraction of >40% were considered an un-successful surgery and excluded from the study. (14).
Immune Cell Isolation from the Heart, Spleen, Bone Marrow, and Blood. BMC were isolated from the femurs of WT C57BL/6 mice as previously described (14, 15) . PBL were isolated from blood collected from mice using a heparinized syringe and centrifuged for 10 min at 1000 revolutions per minute (rpm). The concentrated buffy coat layer was collected, washed with phosphate-buffered saline (PBS), and centrifuged for 5 min at 1000 rpm. De-identified human buffy coat samples were attained from Temple University Hospital and University of Campania "Luigi Vanvitelli" from patients who were naïve to β-blockers or were taking either metoprolol or carvedilol at the time of sample collection, inclusive of patients with hypertension, diabetes mellitus, coronary artery disease and heart failure ( Table 1) . Mouse spleens were isolated and underwent manual digestion in PBS using a syringe plunger until a single cell suspension was Migration Assay. Freshly isolated BMC or PBL were plated on 8 μm transmembrane inserts (Corning; Corning, NY) in a 24-well plate containing vehicle (Veh) or CCL2 (100 ng/mL), as previously described (15) . Cells were stained with Hoechst and migration was imaged after 4h.
Cells were visualized at 10X magnification using a Nikon Eclipse microscope and analyzed from 10 random fields per treatment.
Reverse Transcription Quantitative PCR. cDNA was synthesized from the total RNA of spleen, BMC or PBL samples using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Reverse transcription quantitative PCR (RT-qPCR) was performed to assess CCR2
and VCAM-1 expression with SYBR® Select Master Mix (Applied Biosystems) in triplicate for each sample using primers listed in Supplemental Table 1 at an annealing temperature of 60.1°C.
All RT-qPCR data was analyzed using Applied Biosystems Comparative CT Method (ΔΔCT). Each assay was performed in a minimum of 3 independent experiments.
Study approval. All animal procedures and experiments were carried out according to the National Institutes of Health Guidelines on the Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. Human buffy coat samples and data were not collected specifically for our study and no one on our study team has access to the subject identifiers linked to the specimens or data, thus our study is not considered human subjects research and did not require institutional review board approval. 
